COMMUNIQUÉS West-GlobeNewswire

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
01/10/2026
Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy® (injectable semaglutide 7.2 and 2.4 mg) treatment. 9 in [...]
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
01/10/2026
-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with [...]
Nxera Announces Successful Resolution of miniG Patent Infringement Action
01/10/2026
Tokyo, Japan and Cambridge and London, UK, 30 September 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has entered [...]
RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals
01/10/2026
New program introduces students and young adults to careers in radiology through mentorship, digital experiences and hands-on learning. OWINGS MILLS, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a [...]
Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
01/10/2026
KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek ’s list of [...]
Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
01/10/2026
Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Rakovina [...]
Allogenetics Appoints Dr. Olaf Schermeier as Chairman of the Advisory Board
01/10/2026
Hanover, Germany, October 01, 2026 – Allogenetics today announced the appointment of Olaf Schermeier, PhD, as Chairman of its Advisory Board. Dr. Schermeier brings more than 25 years of industry experience, including [...]
Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
01/10/2026
In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in [...]
Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
01/10/2026
Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Numab Therapeutics (“Numab [...]
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
01/10/2026
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress [...]
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people [...]
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
01/10/2026
Professional microneedling and nano-needling device launches in UK, Ireland, Germany, France, Spain and Portugal LONG BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems (Nasdaq: SKIN), home to flagship [...]
Le SkinStylus® SteriLock MicroSystem de SkinHealth Systems désormais disponible sur le marché européen
01/10/2026
Le dispositif professionnel de microneedling et de nanoneedling fait son entrée au Royaume-Uni, en Irlande, en Allemagne, en France, en Espagne et au Portugal LONG BEACH, Californie, 01 oct. 2026 (GLOBE NEWSWIRE) -- [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG ( [...]
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
01/10/2026
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD Phase 1 study is evaluating the safety, tolerability and [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients [...]
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
01/10/2026
New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals 1-3 Advanced AI-enabled analysis of imaging [...]
IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
01/10/2026
IBA to offer QUANTM ® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics Louvain-la-Neuve, Belgium – October 1st, 2026, 7 a.m. – IBA (Ion [...]

Pages